Lv1
10 积分 2022-06-13 加入
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
21天前
已完结
Conversion to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular oedema
29天前
已完结
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
1个月前
已完结
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
1个月前
已完结
Navigating resistance to ALK inhibitors in the Lorlatinib Era: a comprehensive perspective on NSCLC
6个月前
已完结
An integrated approach to cardioprotection in lymphomas
8个月前
已完结
Selected pharmacologic characteristics of idarubicin and idarubicinol
8个月前
已关闭
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
9个月前
已完结
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
9个月前
已完结
皖公网安备34019202002308
